Accepted Manuscript

Amifostine-conjugated pH-sensitive calcium phosphate-covered magneticamphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer

Wei-Ming Li, Chih-Sheng Chiang, Wei-Chen Huang, Chia-Wei Su, Min-Yu Chiang, Jian-Yi Chen, San-Yuan Chen

PII:	S0168-3659(15)30188-7
DOI:	doi: 10.1016/j.jconrel.2015.10.020
Reference:	COREL 7929
To appear in:	Journal of Controlled Release

Received date:26 January 2015Revised date:1 October 2015Accepted date:13 October 2015

Please cite this article as: Wei-Ming Li, Chih-Sheng Chiang, Wei-Chen Huang, Chia-Wei Su, Min-Yu Chiang, Jian-Yi Chen, San-Yuan Chen, Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer, *Journal of Controlled Release* (2015), doi: 10.1016/j.jconrel.2015.10.020

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Amifostine-ConjugatedpH-SensitiveCalciumPhosphate-CoveredMagnetic-AmphiphilicGelatinNanoparticlesforControlledIntracellularDualDrugRelease forDual-Targeting inHER-2-OverexpressingBreastCancer

Wei-Ming Li^a, Chih-Sheng Chiang^a, Wei-Chen Huang, Chia-Wei Su, Min-Yu Chiang, Jian-Yi Chen, San-Yuan Chen*

Department of Materials Sciences and Engineering National Chiao Tung University, Hsinchu, 30010, Taiwan E-mail: sanyuanchen@mail.nctu.edu.tw

^{*}Correspondence should be addressed to the following: San-Yuan Chen, Department of Materials Science and Engineering, National Chiao Tung University, No. 1001, Ta-Hsueh Rd., Hsinchu, Taiwan 300, R.O.C. Email: <u>sanyuanchen@mail.nctu.edu.tw</u>

^aWei-Ming Li and Chih-Sheng Chiang contributed equally to this work.

Abstract

We developed a surfactant-free method utilizing amifostine to stably link a targeting ligand (Herceptin) to amphiphilic gelatin (AG)-iron oxide@calcium phosphate (CaP) nanoparticles with hydrophobic curcumin (CUR) and hydrophilic doxorubicin (DOX) encapsulated in the AG core and CaP shell (AGIO@CaP-CD), respectively. This multi-functional nanoparticle system has a pH-sensitive CaP shell and degradable amphiphilic gelatin (AG) core, which enables controllable sequential release of the two drugs. The dual-targeting system of AGIO@CaP-CD (HER-AGIO@CaP-CD) with a bioligand and magnetic targeting resulted in significantly elevated cellular uptake in HER2-overexpressing SKBr3 cells and more efficacious therapy than delivery of targeting ligand alone due to the synergistic cell multi-drug resistance/apoptosis-inducing effect of the CUR and DOX combination. This nanoparticle combined with Herceptin and iron oxide nanoparticles not only provided a dual-targeting functionality, but also encapsulated CUR and DOX as a dual-drug delivery system for the combination therapy. This study further demonstrated that the therapeutic efficacy of this dual-targeting co-delivery system can be improved by modifying the application duration of magnetic targeting, which makes this combination therapy system a powerful new tool for in vitro/in vivo cancer therapy, especially for HER2-positive cancers.

Download English Version:

https://daneshyari.com/en/article/10612679

Download Persian Version:

https://daneshyari.com/article/10612679

Daneshyari.com